Mesoblast Limited
Ryoncil
steroid-refractory acute graft versus host disease (SR-aGvHD)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Ryoncil in steroid-refractory acute graft versus host disease (SR-aGvHD) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“The final protocol design for the Phase 3 trial of Ryoncil® as part of the second-line treatment regimen in adults with steroid-refractory acute graft versus host disease (SR-aGvHD), a population approximately three times the size of the pe”